Human clinical trials could begin as early as next year
A team of researchers at the University of Georgia’s Regenerative Bioscience Center and ArunA Biomedical, a UGA startup company, have developed a new treatment for stroke that reduces brain damage and accelerates the brain’s natural healing tendencies in animal models. They published their findings in the journal Translational Stroke Research.
The research team led by UGA professor Steven Stice and Nasrul Hoda of Augusta University created a treatment called AB126 using extracellular vesicles (EV), fluid-filled structures known as exosomes, which are generated from human neural stem cells.
Fully able to cloak itself within the bloodstream, this type of regenerative EV therapy appears to be the most promising in overcoming the limitations of many cell therapies—with the ability for exosomes to carry and deliver multiple doses—as well as the ability to store and administer treatment. Small in size, the tiny tubular shape of an exosome allows EV therapy to cross barriers that cells cannot.
“This is truly exciting evidence, because exosomes provide a stealth-like characteristic, invisible even to the body’s own defenses,” said Stice, Georgia Research Alliance Eminent Scholar and D.W. Brooks Distinguished Professor in the College of Agricultural and Environmental Sciences. “When packaged with therapeutics, these treatments can actually change cell progression and improve functional recovery.”
Following the administration of AB126, the researchers used MRI scans to measure brain atrophy rates in preclinical, age-matched stroke models, which showed an approximately 35 percent decrease in the size of injury and 50 percent reduction in brain tissue loss—something not observed acutely in previous studies of exosome treatment for stroke.
Outside of rodents, the results were replicated by Franklin West, associate professor of animal and dairy science, and fellow RBC members using a porcine model of stroke—the only one of its kind in the U.S.
Based on these pre-clinical results, ArunA Biomedical plans to begin human studies in 2019, said Stice, who is also chief scientific officer of ArunA Biomedical.
“Until now, we had very little evidence specific to neural exosome treatment and the ability to improve motor function,” said Stice. “Just days after stroke, we saw better mobility, improved balance and measurable behavioral benefits in treated animal models.”
Named as part of the ‘stroke belt’ region, Georgia continues to exceed the national average in stroke deaths, which is the third leading cause of death in the U.S., with more than 140,000 Americans dying each year, according to the Centers for Disease Control and Prevention.
ArunA recently unveiled advances to the company’s proprietary neural cell platform for the production of exosome manufacturing. Today, ArunA’s manufacturing process positions the company to produce AB126 exosomes at a scale to meet early clinical demand. The company has plans to expand this initiative beyond stroke for preclinical studies in epilepsy, traumatic brain and spinal cord injuries later this year.
The Latest on: Stroke treatment
via Google News
The Latest on: Stroke treatment
- Walking Speed Following Stroke a Good Predictor of Recovery?on July 2, 2021 at 10:17 am
Stroke survivors with a walking speed of at least 0.8 m/sec can improve their ability to simultaneously walk and perform a second task following training, new research suggests.
- Methodist Rehabilitation Center uses some of the largest, greatest technology for stroke recoveryon July 2, 2021 at 6:00 am
The stroke rate for people between the ages of 18 and 45 has sparked alarmingly in the recent decades, increasing more than 40 percent, according to the American Heart Association. The caseload at the ...
- Care for Stroke Patients Did Not Falter During the Pandemicon July 1, 2021 at 2:32 pm
Acute stroke care in the U.S. was subject to few disruptions during the COVID-19 pandemic, according to registry data. Among hospitals participating in the Get With The Guidelines (GWTG)-Stroke ...
- Diverse Pipeline for Repurposing Drug Company Includes Treatments for Idiopathic Pulmonary Fibrosis and Chronic Cough, Pancreatic Cancer and Strokeon July 1, 2021 at 11:59 am
(AGN:CSE; AGNPF:OTCQB; AGW:FSE) announced the launch of a new clinical research program that will evaluate the use of the drug Ifenprodil (NP-120) in treating pancreatic cancer. The announcement ...
- Governor Signs Antonio's Stroke Legislationon July 1, 2021 at 10:01 am
One of your neighbors posted in Politics & Government. Click through to read what they have to say. (The views expressed in this post are the author’s own.) ...
- Viz.ai Wins CE Mark for AI Stroke Solutionon July 1, 2021 at 7:24 am
Viz.ai’s intelligent care coordination system connects multidisciplinary care teams earlier, coordinates care, and puts patients first with the company’s software suite, which has been clinically ...
- Viz.ai sets its sights across the pond with CE mark for stroke-detecting AIon June 30, 2021 at 9:12 am
With a recent influx of more than $70 million in a series C financing and, now, a shiny new CE mark for its stroke-spotting artificial intelligence software, Viz.ai is ready to take its talents to ...
- Viz.ai wins CE mark for AI-powered stroke care softwareon June 30, 2021 at 7:54 am
Viz.ai announced today that it received CE mark approval for its flagship Viz LVO AI-based stroke care software platform.
- Heat stroke: A doctor offers tips to stay safe as temperatures soaron June 30, 2021 at 7:46 am
Staying hydrated is key to avoiding heat stroke and other heat-related health problems. FocusStocker/Shutterstock.comI easily remember laughing at Wile E. Coyote trying to catch the Road Runner while ...
- AI That Detects Post-Stroke Depression Type Can Help Stroke Survivors Get Right Treatmenton June 29, 2021 at 1:07 pm
Summary: New AI technology can detect a patient’s stroke depression type, and improve treatment options. An AI developed by Japanese researchers might soon help stroke survivors get the right ...
via Bing News